Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis.
Business Wire › September 18, 2008
Linked as:
Extract
Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis.
Company's Commitment to Multiple Sclerosis Patients Remains Strong
MONTREAL -- Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada. Nearly 20 presentations will focus on the company's products: TYSABRI([R]) (natalizumab), which offers MS patients a new level of efficacy, and AVONEX([R]) (Interferon beta-1a), the most prescribed MS therapy worldwide, as well as its pipeline featuring compounds targeting unique approaches for development in MS. These dat...See the full content of this document
Sponsored links
